Published in Health Policy Plan on March 01, 1997
Economic evaluations of non-communicable disease interventions in developing countries: a critical review of the evidence base. Cost Eff Resour Alloc (2006) 1.25
Valuing climate change impacts on human health: empirical evidence from the literature. Int J Environ Res Public Health (2009) 1.18
A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med (1995) 4.21
Intramuscular injections within 30 days of immunization with oral poliovirus vaccine--a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med (1995) 2.81
Current situation and control strategies for resurgence of diphtheria in newly independent states of the former Soviet Union. Lancet (1996) 2.78
Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis (1992) 2.55
Improving primary health care through systematic supervision: a controlled field trial. Health Policy Plan (1995) 2.27
Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol (1998) 2.24
Differential diagnosis of acute flaccid paralysis and its role in poliomyelitis surveillance. Epidemiol Rev (2000) 2.06
Stopping poliovirus vaccination after eradication: issues and challenges. Bull World Health Organ (2000) 2.00
Standardized diagnosis of pneumonia in developing countries. Pediatr Infect Dis J (1992) 1.95
Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2000) 1.67
Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis (2000) 1.67
Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA (1996) 1.64
Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication. Int J Epidemiol (2001) 1.53
Reporting efficiency during a measles outbreak in New York City, 1991. Am J Public Health (1993) 1.53
Vaccine-associated paralytic poliomyelitis. N Engl J Med (1993) 1.39
Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin Infect Dis (1998) 1.38
Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med (1994) 1.23
Outbreaks of paralytic poliomyelitis, 1976-1995. J Infect Dis (1997) 1.20
Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis (2001) 1.20
Disease eradication as a public health strategy: a case study of poliomyelitis eradication. Bull World Health Organ (2000) 1.18
Measles eradication: is it in our future? Am J Public Health (2000) 1.12
Paralytic poliomyelitis in Romania, 1984-1992. Evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection. Am J Epidemiol (1994) 1.09
Tetanus surveillance--United States, 1989-1990. MMWR CDC Surveill Summ (1992) 1.09
Prevention of secondary transmission of pertussis in households with early use of erythromycin. Am J Dis Child (1992) 1.01
Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet (1994) 1.00
Concurrent outbreaks of pertussis and Mycoplasma pneumoniae infection: clinical and epidemiological characteristics of illnesses manifested by cough. Clin Infect Dis (1995) 0.95
A study evaluating poliovirus antibodies and risk factors associated with polio seropositivity in low socioeconomic areas of Pakistan. Vaccine (2013) 0.90
Tetanus surveillance--United States, 1991-1994. MMWR CDC Surveill Summ (1997) 0.89
Outbreak of poliomyelitis in Gizan, Saudi Arabia: cocirculation of wild type 1 polioviruses from three separate origins. J Infect Dis (1997) 0.83
Evaluation of a single dose of diphtheria toxoid among adults in the Republic of Georgia, 1995: immunogenicity and adverse reactions. J Infect Dis (2000) 0.82
Commentary: the unfolding story of global poliomyelitis eradication. J Infect Dis (1997) 0.82
Status of poliomyelitis eradication in Europe and the Central Asian republics of the former Soviet Union. J Infect Dis (1997) 0.81
Widespread paralytic poliomyelitis in Pakistan: A case-control study to determine risk factors and implications for poliomyelitis eradication. J Infect Dis (2000) 0.80
Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992-1994. J Infect Dis (1997) 0.80
Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis (1997) 0.79
Epidemic diphtheria in the Republic of Georgia, 1993-1996: risk factors for fatal outcome among hospitalized patients. J Infect Dis (2000) 0.78
Stopping a polio outbreak in the post-eradication era. Dev Biol (Basel) (2001) 0.78
Vaccine-associated paralytic poliomyelitis in the United States: no evidence of elevated risk after simultaneous intramuscular injections of vaccine. Pediatr Infect Dis J (1995) 0.76
Tetanus immunization: concerns about the elderly and about diphtheria reemergence. J Gen Intern Med (1994) 0.75
Possible global strategies for stopping polio vaccination and how they could be harmonized. Dev Biol (Basel) (2001) 0.75
Evaluation of a single dose of diphtheria-tetanus toxoids among adults in Odessa, Ukraine, 1995: immunogenicity and adverse reactions. J Infect Dis (2000) 0.75
Poliomyelitis in Angola: current status and implications for poliovirus eradication in Southern Africa. J Infect Dis (1997) 0.75
Risk factors for diphtheria: a prospective case-control study in the Republic of Georgia, 1995-1996. J Infect Dis (2000) 0.75